WORCESTER, Mass.--(BUSINESS WIRE)--CytRx Corporation’s (NASDAQ:CYTR) majority-owned subsidiary, Worcester, Massachusetts-based RXi Pharmaceutical Corporation (RXi), today announced that leading RNA interference (RNAi) scientists received consent from their respective research institutions and have signed agreements to join RXi’s scientific advisory board. Members of the RXi scientific advisory board will include RNAi technology leaders Craig C. Mello, Ph.D., the 2006 Nobel Laureate for co-discovering RNAi; Tariq M. Rana, Ph.D., inventor of fundamental technology for stabilizing RNAi and of RNAi nanotransporters; Gregory J. Hannon, Ph.D., discoverer of RNAi mechanism (RISC) and short hairpin RNAi (shRNAi); and Michael P. Czech, Ph.D., a leader in the application of RNAi to diabetes and obesity. Drs. Mello, Rana and Czech are currently scientific advisors to CytRx, and the new advisory agreements with the four scientists will become effective upon RXi’s achievement of a funding milestone.
